IMPORTANCE Black infants born preterm face high rates of recurrent wheezing throughout infancy. Vitamin D supplementation has the potential to positively or negatively affect wheezing through modulation of the pulmonary and immune systems.
W heezing is a common complication of prematurity. Early environmental and iatrogenic exposures may perturb the development of the lung, airway, or immune system and lead to recurrent wheezing. Substantial evidence suggests vitamin D is important in multiple pathways relevant to the development of wheezing in young children, including regulating inflammation, response to pathogens, lung and airway development, and propensity to allergic disease. [1] [2] [3] [4] [5] [6] [7] [8] [9] Preterm infants, with developmentally immature pulmonary and immune systems perturbed by preterm birth, may be particularly vulnerable to any positive and negative effects of vitamin D. Black infants experience higher rates of both prematurity and prematurity-associated wheezing, and previous epidemiological work suggests that race may affect the relationship between vitamin D exposure and wheezing, leading to the design of the present study focusing exclusively on black infants. 10, 11 The Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy (D-Wheeze) Study assessed the effectiveness of 2 vitamin D supplementation strategies in black infants born preterm: (1) sustained supplementation with 400 IU/d of cholecalciferol until 6 months of age adjusted for prematurity, or (2) cessation of supplementation when the infant was taking 200 IU/d or more from diet. This trial focused on clinical outcomes as well as surrogate markers of pulmonary health, allergy, and bone health.
Methods
This study was approved by the institutional review board at each participating institution. The protocol is available in Supplement 1. Written informed consent was obtained from the infants' parents prior to drawing any eligibility laboratories that were not obtained as part of clinical care and prior to randomization of eligible infants.
Study Design and Participants
We conducted a masked placebo-controlled randomized clinical trial of the effectiveness of 2 vitamin D supplementation strategies in black infants born at 28 0/7 to 36 6/7 weeks' gestational age (GA). Patients were enrolled between January 2013 and January 2016; the follow-up window closed March 2017. Infants were recruited from University Hospitals Cleveland Medical Center (Cleveland, Ohio), MetroHealth Medical Center (Cleveland, Ohio), the Medical University of South Carolina (Charleston), and Montefiore Medical Center (Bronx, New York). Infants were randomized to receive 400 IU of cholecalciferol daily until 6 months' adjusted age (sustained group) or until they were taking at least 200 IU/d of vitamin D from formula or human milk fortifier (diet-limited group). Patients received open-label multivitamin until they were consuming 200 IU/d of cholecalciferol from formula or human milk fortifier, after which they received masked study drug (liquid cholecalciferol or a placebo, dispensed in an amber bottle). Parents, clinical caregivers, and study staff with patient contact were masked. Exclusively breastfed infants received openlabel multivitamin as long as they were exclusively breastfed, up to 12 months' adjusted age. The study protocol did not dictate what infants were fed.
Study visits occurred at 3, 6, 9, and 12 months of age, adjusted for degree of prematurity, in the infant's home and in the clinic. A monthly diet questionnaire was completed until 6 months' adjusted age (or longer if exclusively breastfed) to assess 25-hydroxyvitamin D (25[OH]D) intake.
Infants were eligible for enrollment if they were 28 0/7 to 36 6/7 weeks' GA at birth, the family identified the child as black or African American, they received 28 days or less of supplemental oxygen, were admitted to a participating nursery as a neonate, were 40 6/7 weeks' adjusted GA or younger at enrollment, and lived within a predefined geographic area at each site. Infant race was considered "black" or "African American" if the parents affirmed that they believed one of those descriptors applied to their infant. Infants were not eligible if they were diagnosed as having bronchopulmonary dysplasia; had a preexisting diagnosis of moderate to severe osteopenia of prematurity and/or alkaline phosphatase level greater than 700 U/L (to convert to μkat/L, multiply by 0.0167); a history of fracture; a history of gastrointestinal surgery including for necrotizing enterocolitis, known gastrointestinal malabsorption, a major congenital anomaly, a congenital pulmonary or airway disorder, documented wheezing, or stridor prior to enrollment; previous vitamin D supplementation with more than 400 IU/d; or the family planned to move out of the region. Infants were also ineligible if their serum phosphorus concentration was outside of the range of 4.0 to 9.5 mg/dL (to convert to mmol/L, multiply by 0.323) or serum calcium was outside of the range of 8.5 to 10.7 mg/dL (to convert to mmol/L, multiply by 0.25). A 25(OH)D concentration less than 10 ng/mL or greater than 80 ng/mL also made infants ineligible (to convert to nmol/L, multiply by 2.496). Eligible ranges for laboratory values were modified in the first year of enrollment (eMethods in Supplement 2). Serum bone markers of health and 25(OH)D levels were processed at each site's clinical chemistry laboratory.
Adherence was estimated by weighing bottles of either open-label multivitamins or masked study drug before they were dispensed and after they were returned. Ideal adherence was defined as a weight difference averaging approximately 1 g/d.
Adverse Event Monitoring
The trial was monitored by a National Institutes of Healthconvened data and safety monitoring board. A medical monitor reviewed certain categories of adverse events and laboratory values out of a predetermined range (eMethods in Supplement 2). She had independent authorization to either remove a child from the study or refer for further medical care. She was authorized to view group allocation as needed for safety, but did not access this information.
Randomization, Stratification, and Blinding
Infants were randomized with randomly permuted blocks, sizes 2 to 6, using computer-generated random numbers. Randomization was stratified by site and whether the infant had received any of their own mother's milk within 24 hours of randomization. Twins and triplets were randomized together. Families, clinical caregivers, and study staff were blinded to assignment and block size.
Outcomes
The primary outcome was parent-reported recurrent wheezing (≥2 episodes of wheezing with or without an infection) by 12 months' adjusted age, using a modified International Study of Asthma and Allergies in Childhood questionnaire. 12 These questions have been shown to perform well in infants born preterm. 13 Recurrent wheezing was defined as 1 report of more than 1 wheezing episode since the last interview or reports of single wheezing episodes at multiple visits. The ascertainment of recurrent wheezing was standardized with other concurrent trials.
14,15
Secondary outcomes included parental report of upper and lower respiratory tract infections, pulmonary medications, hospitalization and emergency department visits, allergies, and eczema. These were assessed by questionnaire at each follow-up point. The modified Asthma Predictive Index was calculated, which yields a positive or negative prediction. 16 Eosinophil counts were obtained at 12 months.
Scoring Atopic Dermatitis skin examinations for eczema were completed at each follow-up point; Scoring Atopic Dermatitis scores range from 0 to 103; and a value of 25 or more indicates moderate to severe eczema. 17 Circulating 25(OH)D3
concentrations were measured at the 3-, 6-, and 12-month visits, using the immunoassays that were standard of care at each site. Clinical recommendations for infants generally target levels 20 ng/mL or greater. 18, 19 Serum markers of bone health (alkaline phosphatase, calcium, phosphorus) were also measured at the clinical chemistry laboratory at each site. A speed-of-sound measure of tibial bone density assessment was done at 12 months. Published norms have described the mean and 2 SDs below the mean for 1-year-old girls to be 3139 m/s and 2919 m/s, respectively, and for boys to be 3189 m/s and 2871 m/s, respectively. 20 Values less than 2 SDs below the mean were considered abnormal. A panel of allergen-specific IgE antibodies (ImmunoCAP Phadiatop Infant; Phadia AB) was obtained at 12 months. 21 The panel included common food and inhalant allergies (egg, cow's milk, peanut, shrimp, cat, dog, house dust mite, birch, timothy, ragweed, and wall pellitory). Results range from 0 to 100 k A /L; a level of 0.35 k A /L or greater is considered positive.
Statistical Analysis
Power and Sample Size Based on a baseline rate of recurrent wheezing of 30%, a 2-sided significance level of .05, and a power of 80% to detect a relative risk of 1.6, a sample size of 115 infants per group was estimated. Allowing for 15% loss to follow-up and 20% of enrolled infants to be part of a twin pair, a sample size of 300 infants was planned. In the absence of a generally accepted minimal clinically important difference for studies of recurrent wheezing in infancy, a relative risk of 1.6 was chosen to be sufficiently large to be meaningful at face value and to be plausible based on prior studies.
10
Baseline Characteristics Standard summary statistics were used to describe baseline characteristics. For characteristics measured at the family level, such as maternal age, Pearson χ 2 tests or 2-sample t tests were used. For comparisons of patient-level characteristics, such as birth weight, we used generalized estimating equations (GEEs) with exchangeable working covariance to reflect within-family covariance. All statistical analyses were conducted using SPSS version 25 (IBM Corp) or SAS for Windows 9.4 (SAS Institute Inc).
Primary Outcome
Analyses were based on a modified intent-to-treat approach. Because the primary outcome was a composite of longitudinal points, and most participants who withdrew did so before 3 months (Figure 1 ), withdrawn participants were not included. The 4 participants who were lost to all follow-up were not included in the primary analysis. Type I error was assumed to be .05, except for the primary outcome. One interim analysis was performed. The significance level used at the interim analysis was .003, while the significance level used at the final analysis was .047. For the primary outcome of recurrent wheezing, we used GEEs to account for the nonindependence of twins and triplets and to estimate the risk ratio and risk difference.
22,23 Two
Poisson regression models, adjusted and unadjusted, were planned a priori, with the unadjusted model considered primary. Covariates in the secondary adjusted model included randomization strata (site and maternal milk at enrollment), GA, time in study, and baseline covariates associated with recurrent wheezing within a significance level of .10. Adjustment for unbalanced baseline characteristics not associated with recurrent wheezing was not planned because, if a covariate is not strongly related to an outcome but is imbalanced between groups, adjustment for an imbalanced covariate may dilute the effect of treatment.
24
A pattern mixture modeling approach was used to assess the sensitivity of the primary finding to missing data. This included 8 participants whose recurrent wheezing outcome could not be determined due to a missing 12-month visit and not having yet met the definition of recurrent wheezing. We considered a range of scenarios where the outcome was no longer independent of whether or not the data were missing (ie, not missing at random). This missing data approach is detailed in the eMethods in Supplement 2.
Secondary Outcomes
For secondary binary outcomes that were planned a priori, we fit unadjusted Poisson GEE regression models. For continuous outcomes, we used linear GEE models. Secondary outcomes were also analyzed by follow-up point. Corresponding 95% CIs of risk and mean difference were generated from these models.
Post Hoc Analyses
Post hoc analyses assessed the role of baseline maternal milk status and sex on treatment outcomes through modeling of interaction with randomization group. In addition, a post hoc analysis of the primary outcome was conducted, which added baseline unbalanced covariates (P < .05) to the adjusted model.
Results

Characteristics of the Trial Population
Of the 300 infants enrolled in the study, 18 withdrew from the study and 1 died while cosleeping ( Figure 1 ). Follow-up rates of surviving nonwithdrawn infants at the 3-, 6-, 9-, and 12-month visits were 97.9%, 96.5%, 95.0%, and 94.0%, respectively. Due to missing 12-month visits in infants who had not yet met criteria for recurrent wheezing, we were unable to determine recurrent wheezing status for 8 children, and these cases were considered as missing data in the primary analysis. Overall, the population had multiple risk factors for wheezing, including high rates of asthma in the family, smokers in the home, and other children younger than 5 years of age in the home ( Table 1) . At the first diet screen, 1 month after enrollment, 61.4% of those receiving maternal milk at randomization and 94.1% of those not receiving maternal milk were above the 200 IU/d threshold to transition to blinded study drug. At the 3-month adjusted age point, 90.2% of the infants receiving maternal milk at randomization and 100% of those not receiving maternal milk had been transitioned to blinded study drug. Feeding patterns are described in eTable 1 in Supplement 2.
Adherence was estimated for participants who received their final bottle of study drug and returned all bottles. Among participants who received their final bottle of study drug, rates of return of all bottles were 75 of 141 (53.2%) in the sustained group and 60 of 133 (45.1%) in the diet-limited group. Average estimated daily intake was 0.94 g in the sustained group and 0.91 g in the diet-limited group. Table 2) . Missing data sensitivity analysis supports the primary finding, in that associated averaged P values across a range of imputation scenarios were consistently less than .047 (eMethods in Supplement 2).
Primary Outcome
A planned model of recurrent wheezing adjusting for randomization strata, time in study, GA, and the variables associated with recurrent wheezing in bivariate analyses was also run. In this model, recurrent wheezing was significantly decreased in the sustained supplementation group (relative risk, 0.62 [95% CI, 0.44 to 0.87]; P = .005) (eTable 2 in Supplement 2).
Secondary Outcomes
For secondary outcomes, values were determined for each infant included, so there were no missing outcomes in the analyses. No significant differences between groups were seen in total medically attended illnesses or markers of allergy or bone health ( Table 2 ). The Asthma Predictive Index was positive for 
Adverse Events
There were no statistically significant differences between the groups in the number of infants experiencing any adverse events or serious adverse events ( 
Post Hoc Analyses
Median achieved circulating 25(OH)D concentrations were greater than 30 ng/mL at follow-up ( Figure 2 and eTable 5 in Supplement 2). Separation between groups was primarily seen in the infants who were not receiving maternal milk at randomization. However, there was no significant interaction between maternal milk at randomization and group (P = .20).
There was also no significant interaction between sex and randomization group (P = .32).
Discussion
In this randomized clinical trial of black preterm infants, sustained supplementation with vitamin D compared with diet-limited supplementation resulted in a reduced risk of recurrent wheezing by 12 months' adjusted age. Neither group demonstrated superiority in terms of bone health or allergic disease. Both supplementation strategies targeted a total daily intake between 200 and 1000 IU of vitamin D, generally within the high and low ranges recommended by the American Academy of Pediatrics and Institute of Medicine 18, 19, 25 ; infants consuming a high volume of formula designed for feeding preterm infants may have exceeded that range. Infant dietary vitamin D intake also tends to increase over time; therefore, total intake was not constant over the study period. Epidemiologic studies in a northern Finland cohort showed an association between infant supplementation and allergy and atopy later in life, 26 and other cohort studies have found increased wheezing or asthma in black infants being supplemented with up to 400 IU/d. 10,11 However, this study suggests At baseline, the sample sizes were 42 and 56 in the sustained and diet-limited groups, respectively, for recurrent wheezing and 93 and 78 for no recurrent wheezing; at 3 months, sample sizes were 42 and 55 in the sustained and diet-limited groups, respectively, for recurrent wheezing and 88 and 78 for no recurrent wheezing. of studies in other populations should not be extrapolated to preterm infants who may be in a critical developmental window with regard to the effects of vitamin D on the pulmonary and immune systems. This effectiveness study has several strengths, including targeting clinically relevant outcomes in a high-risk and understudied population of preterm infants, with low rates of attrition during the study. Validated questions were used that have been shown to perform well in this population and were concurrently used in other trials.
12-15,38 Stratification of randomization by receipt of maternal milk intake in the prior 24 hours aimed to balance maternal milk exposure between randomization groups, due to the immunologic and dietary differences between breastfed and exclusively formula fed infants, including the potential protective role of maternal milk with regard to wheezing and infection.
Limitations
This study has several limitations. First, despite the use of a validated questionnaire, there is potential for misclassification of wheezing by questionnaire. Second, the study was not powered to detect significant differences in secondary outcomes such as hospitalization or serious adverse events. Third, resource utilization, such as medically attended illnesses, are also highly driven by nonbiological social factors. Fourth, the significance level for a priori secondary outcomes was not adjusted for multiple comparisons. Therefore, statistically significant results in secondary outcomes, such as the analyses by follow-up point, should be interpreted as exploratory. Fifth, this effectiveness study tested 2 dosing regimens within the bounds of common supplementation recommendations in a population of black preterm infants born at 28 0/7 to 36 6/7 weeks' GA with a paucity of major neonatal morbidities. The sustained strategy may or may not reflect the optimum dosing strategy in this population; the results cannot be generalized to support the efficacy or adverse event profiles of higher doses; nor can they be generalized to infants of other races, those born at less than 28 weeks' GA, or infants with bronchopulmonary dysplasia.
Conclusions
Among black infants born preterm, sustained supplementation with vitamin D, compared with diet-limited supplementation, resulted in a reduced risk of recurrent wheeze by 12 months' adjusted age. Future research is needed to better understand the mechanisms and longer-term effects of vitamin D supplementation on wheezing in children born preterm.
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160
Exposing the immature immune system to vit. D may predispose infants to asthma and allergy later in life. In 161 vitro studies and mouse models suggest that vitamins may skew T cells towards either less allergic T-helper 1 162 (vitamins B 6 , E, and C) or a more allergic T-helper 2 (vitamins D and A) phenotypes.
9 10 64 65 91-95 There may be 163 a critical developmental window for such an effect. 36 If this is the case, premature infants could be more or less 164 vulnerable than term infants. Milner et al. (2004) found that black infants exposed to multivitamins in the first 6 165 mo. of life had a higher risk of asthma in early childhood, and that formula-fed vitamin-exposed infants of all 166 races experience more food allergies. Terminology: In our review of the relevant literature, data are presented on both wheezing in infancy and 217 asthma, but this should not be interpreted as a claim of equivalency. The focus of this study will be persistent 218 wheezing in the first year of life, although we will calculate an asthma predictive index as a secondary outcome. 
247
Serum 25(OH)D3 levels were non-significantly higher in the 960 IU group at 6 weeks of age, and the authors 248 concluded that 200-400 IU/day was sufficient to maintain bone health in preterm infants. In another study of 70 249 preterm infants, no difference was found in bone mineral status at 3 months or 9-11 years of age among 250 infants who had been randomized to 500 IU/day versus 1000 IU/day supplementation in early infancy.
108
251 Interestingly, exposure to breast-milk was positively correlated with lumbar bone mineral density at school age 252 despite the lower levels of vit. D in breast milk compared to formula.
253
There is very little evidence that either the higher or lower range of current recommendations is 254 superior for bone health in preterm infants. These studies have largely not addressed (1) impact on 255 pulmonary health, (2) the potentially unique needs of black infants, or (3) the needs of healthy infants 256 born moderately preterm and late preterm. This study aims to identify a supplementation strategy that 257 will minimize recurrent wheezing in infancy while safely maintaining bone health. We hypothesize that 258 strategy II (diet-limited) will be sufficient to prevent rickets and the impaired response to infection associated 259 with D deficiency, and will also result in less recurrent wheezing in infancy than strategy I (sustained). 260 261
A6. PRELIMINARY STUDIES 262
Our preliminary data are based on an ongoing cohort study prospectively following infants without BPD born at 263 28 0/7 -34 6/7
wks GA at Rainbow Babies and Children's Hospital (RB&C) (K23 HD056299). This study will enroll 264 300 infants, and as of 6/13/11, 297 subjects had been enrolled from this single center. A questionnaire is 265 administered at 3, 6, 9, and 12 mo. adjusted age to assess respiratory symptoms. Black infants make up 50% 266 of this cohort. Our enrollment rate is on-target and our follow-up rate is 92%, demonstrating the ability to recruit 267 and retain subjects, including a high percentage of minorities and socioeconomically disadvantaged 268 participants. Until the time of this preliminary analysis, the policy of the Rainbow NICU was to supplement (table 4) . Among the infants in this study, 271 55% were discharged from the NICU on a vitamin supplement. After discharge, management was at the 272 discretion of the family and their primary care provider. 273
Overall, black infants experienced more wheezing than white infants. At each assessment time point, black 274 infants who had been discharged on vitamins reported more wheezing than black infants not on vitamins; white 275 infants discharged on vitamins had less reported wheezing than white infants not on vitamins (table 1) . Among 276 those discharged on vitamins, 76% were still taking them at 3 months, and 49% at 6 months. Among infants 277 not discharged on vitamins, 17% were taking them at 3 months, and 16% at 6 months. 278 process of the year-long follow-up. Next, we focus on the subset of 143 infants who had completed the study at 281 the time of the analysis, so that we can restrict our analysis to a group of infants that has had an equal 282 opportunity to experience recurrent wheezing. In a logistic regression adjusted for GA and exposure to breast 283 milk, the odds ratio of recurrent wheezing in white infants (n=73) discharged on vitamins compared to those 284 not discharged on vitamins was 0.63 (95% CI: (0.22, 1.78)), and the adjusted odds ratio of recurrent wheezing 285 in black infants (n=70) discharged on vitamins compared to those not discharged on vitamins was 1.33 286 (95%CI: (0.44, 4.02)). The effect seems to be strongest in the more mature preterm infants, with the 287 adjusted odds ratio for recurrent wheezing in black infants >30 wks GA of 1.55 (95% CI: (0.46, 5.26)), 288 and for black infants >32 weeks of 3.32 (0.553, 19.98). This apparent maturity effect could potentially be due 289 to a critical developmental window, or because the less mature infants have more competing causes of 290 wheezing. Although these numbers are not statistically significant, we would not expect them to be since this is 291 a preliminary analysis of an ongoing study that was not powered for a stratified analysis by race, and infants 292 are still being enrolled and followed. The direction of the estimates for recurrent wheezing in the subset of 293 infants who have completed the study is consistent with the cross-sectional data for all of the enrolled infants 294 (table 1) . Furthermore, this consistent pattern is seen despite some cross-over in vitamin exposure after 295 discharge, which we would expect to bias our results towards the null.
296
Our preliminary data also give us insight into the outpatient feeding practices for healthy black preterm infants 297 in Cleveland. At enrollment (within ~2 wks of anticipated hospital discharge), 36% were receiving only maternal 298 milk. At 3 mo. adjusted age, 4.5% were receiving only maternal milk, 82% were receiving only formula, and 299 13.5% were receiving a combination of formula and maternal milk. By 6 mo. adjusted age, 0% were exclusively 300 breast fed and 95.9% were exclusively formula fed. Therefore, the majority of infants in this population, despite 301 efforts to promote breast feeding, are receiving the bulk of their nutrition from formula enriched with vit. D. 302
Therefore, the question of whether to stop vit. D supplementation when infants reach a threshold dietary intake 303 or leave them on supplementation in addition to their dietary sources is particularly relevant.
304
In a separate pilot study, we enrolled 80 infants born preterm and term, and administered respiratory 305 questionnaires and genotyped the patients for VDR polymorphisms. The best-enrolling site in this pilot was the 306 University Hospitals clinic, which primarily treats socioeconomically disadvantaged black children from 307
Cleveland; we received several calls from parents seeking out our recruiter if they had missed her during their 308 child's visit and expressing willingness to return to the hospital just to participate in the study. This again 309 demonstrates our ability to recruit a population demographically similar to the one in the proposal. 310 311 312 313
The proposed study is innovative because it (1) focuses on an understudied population of infants 28-36 wks 314 GA, and (2) addresses the unique needs of black preterm infants, whereas most nutritional studies in preterm 315 infants have not accounted for potential differences by race, and (3) focuses on the impact of vit. D 316 supplementation on clinically meaningful measures of pulmonary health and overall health, whereas prior 317 332 weeks GA. Infants will be enrolled in the NICU or newborn nursery when they are tolerating full volume feeds 333 and are off oxygen. All infants will receive a daily standard infant multivitamin containing 400 IU of D3 until they 334 are taking at least 200 IU/day of vit. D daily from formula or fortifier. Most infants taking formula will reach this 335 amount by 0-1 mo. adjusted age. Infants will then be randomized to receive either 400 IU of D3/day (Strategy I) 336 or placebo (Strategy II). Study drug will be administered until 6 mo. adjusted age, at which time 337 supplementation will be stopped. Although rates of exclusive breastfeeding beyond 6 mo. are extremely low in 338 this population (0% in our preliminary data), we will continue to provide any exclusively breast-feeding infants 339
B. INNOVATION
with a 400 IU/ml D3 supplement. Study visits will occur at 3, 6, 9, and 12 mo. adjusted age.
340
The primary outcome will be parent-reported recurrent wheezing (>2 episodes of wheezing with or without an 341 infection) between initial hospital discharge and 12 mo. corrected age. Recurrent wheezing will be defined as phosphorous,), and a speed-of-sound bone density assessment. Economic data will be gathered for use in 362 future studies and for availability for meta-analysis, but will not be analyzed as part of this study. 363 364 The ISAAC questionnaire has been validated for use in children. 111 112 A slightly modified version to reflect the shorter assessment intervals and younger children in this study will be used. The phrasing of the core question about wheezing, "wheezing or whistling in the chest," is standardized wording that has also been used in the American Thoracic Society child questionnaire ATS-DLD-78-C, 113 and in the follow-up assessments of multi-center trials studying preterm infants (e.g., NO CLD 114 115 and SUPPORT 116 117 , and in the study on which or preliminary data are based (K23-HD056299) ). Parent-identified wheezing has been shown to have good agreement with concurrent physician auscultation. 118 Additional questions based on the ATS-DLD-78-C will further identify whether wheezing occurred with or without a respiratory infection, for secondary analyses of wheezing episodes by apparent etiology. Such questions are used in clinical practice and are meaningful to providers and patients. Pulmonary medications, hospitalization, ER visits, and outpatient sick visits will also be captured. The Phadiatop® Infant assay, an in vitro test for IgE antibodies to food and inhalant allergens, has been recommended by the NHLBI and NIAID as the biomarker to measure sensitization in infants, It is 96% sensitive and specific.
123
124 The assay yields a positive or negative result for sensitization but does not report the specific antigen. Clinical allergy symptoms will be assessed by questionnaire. The ISAAC questionnaire has been validated for use in children; a modified version to reflect the shorter assessment intervals and younger children will be used. Additional questions about types of allergies and food allergies based on the ATS-DLD-78-C will also be used. Food sensitization in infancy is strongly associated with the risk of childhood asthma. The validated European Taskforce on Atopic Dermatitis SCORAD eczema assessment tool will be completed during the follow-up visits.
126-128 A question about prior diagnoses of eczema excerpted from the ISAAC eczema module will also be used. Eczema in infancy is associated with allergy in childhood. The modified API is determined by recurrent wheezing, history of eczema, parental history of asthma, eosinophilia, sensitization to aeroallergens and foods, and wheezing apart from colds.
129-131 The API will be used to describe differences in risk in the study arms. We expect a similar distribution of family history in the arms, but will examine that assumption.
Safety
Adverse Events e.g., fracture, kidney, stones, rickets, etc.
Clinical adverse events potentially related to vit. D supplementation will result in unblinding and referral to specialty care. Adverse events will be reported to the DSMB, IRB, and NIH in compliance with local and federal guidelines.
Laboratory values
Alkaline phosphatase, , calcium, phosphorous, 25(OH)-D Differences in serum markers of bone health will be compared. Hypocalcemia, hypercalcemia, hypophosphatemia, or hyperphosphatemia will result in unblinding, removal from the protocol, and referral to specialty care. Because the optimal serum levels of vit. D are not known, and because of potentially competing positive and negative clinical outcomes, serum levels of vitamin D will not be used to unblind a patient or remove them from the protocol except in cases of extreme deficiency (level <15 ng/ml) or excess (>80 ng/ml).
Bone Density
Tibial speed of sound Norms have been published for infant and pediatric speed of sound (ultrasound) measurements of bone density.
132-137
Randomization: Infants will be randomized 1:1 to a dosing strategy using permuted blocks. Block size will be 369 randomly varied and investigators and study personnel will be blinded to block size. Randomization will be 370 stratified by site and maternal milk exposure (receiving any maternal breast milk at enrollment). Families, 371 treating physicians, and study staff will be blinded to assignment. Randomization will be performed by the 372 CTSC-supported Case Western Reserve University Center for Clinical Investigation Statistical Sciences Core. 373
Inclusion criteria: (1) 28 0/7 -36 6/7 wks GA at birth; (2) family identifies the child as black or African American; (3) 374 <28 days of supplemental oxygen (subsequent oxygen therapy for <72 hrs for a brief subsequent illness or 375 surgery will be allowed); (4) admitted to the NICU, special care nursery, transitional care nursery, or well-baby 376 nursery as a neonate; and (5) <40 wks corrected GA at enrollment. 377
Exclusion criteria: (1) BPD (>28 days of supplemental oxygen); (2) pre-existing diagnosis of moderate to 378 severe osteopenia of prematurity and/or alkaline phosphatase >700; (3) history of fracture; (4) gastrointestinal 379 surgery, including for NEC; (5) known gastrointestinal malabsorption; (6) major congenital anomaly; (7) 380 congenital pulmonary or airway disorder (e.g., cystic fibrosis, tracheomalacia, swallowing disorder, 381 bronchopulmonary sequestration); (8) documented wheezing or stridor prior to enrollment; (9) previous vit. D 382 supplementation with >400 IU/day; (10) family plans to move more than the pre-determined catchment area at 383 each site (60 miles from CWRU, to be determined before enrollment at each additional site); (11) baseline 384 hypo-or hypercalcemia, hypo-or hyperphosphatemia; and (12) baseline 25(OH)D level <10 ng/ml or >80 385 ng/ml. 386
We will exclude infants born at <28 wks GA or those with BPD (oxygen requirement >28 days), as these 387 infants do not represent the majority of NICU patients, and they are likely to have more early lung injury and 388 architectural developmental abnormalities pre-dating randomization; they are also more likely to have 389 osteopenia of prematurity requiring treatment with higher than usual doses of vit. D, calcium, or phosphorous. 390
The apparently "healthy" infants included represent the majority of preterm infants born in the U.S.. Strategy II: Infants will receive 400 IU/day of D3 in the form of a standard infant multivitamin until they are 396 taking >200 IU/day of vit. D from formula or human milk fortifier. Subsequently, they will receive placebo 397 (color-matched commercially available pediatric compounding solution). 398
Study procedures: Infants will be assessed by home-visits at 3, 6, and 9 mo. adjusted age (If participants are 399 uncomfortable having the study team come to their home or prefer to come to the clinic for any reason, they 400 can be seen in clinic). If additional sites outside of Cleveland are added, the sites may choose to conduct the 3, 401 6, and 9 month visits in the clinic if home visits are not feasible due to that site's infrastructure. A scheduled 402 clinic visit will occur at 12 mo. for physical exam and lab work. A dietary history and reinforcement of study 403 supplement instructions will be done over the phone monthly between study visits until 6 mo adjusted age. The 404 appropriate study medication (multivitamin, D3 supplement, or placebo) will be delivered to the home. A 1 ml 405 syringe will be provided for administration to avoid any unintentional overdoses. 
416
C2. Dosing: This effectiveness study compares supplementation strategies that can be feasibly followed by a 417 family and primary care provider in a busy practice. D3 will be used, as this is the most common form of vit. D 418 in over-the-counter infant supplements. Our preliminary data show that very few black preterm infants in 419
Cleveland are exclusively breast-fed and most mothers stop breast-feeding by 3 mo. adjusted age, so most 420 infants will be receiving a significant amount of vit. D from formula. Intake in both arms is within the current 421 wide range of recommendations for preterm infants. in arm I may slightly exceed the 2010 IOM recommendations for a total intake of <1000 IU/day in infants less 429 than 6 months, and infants in arm II will likely remain within this range ( Total daily enteral D intake (IU/day of diet + supplement) for infant drinking: * 250 ml term formula 250 ml transititional formula 500 ml term formula 500 ml transititional formula 1000 ml term formula 1000 ml transititional formula 1500 ml term formula 1500 ml transititional formula ~500 ~548 ~600 ~895 ~800 ~990 ~1000 ~1285 ~500 ~548 ~200 ~295 ~400 ~590 ~600 ~885 ~300 ~348 ~200 ~295 ~400 ~590 ~600 ~885 ~500 ~548 ~600 ~895 ~400 ~590 ~600 ~885 ~100-500** ~148-548** ~200-600** ~295-895** ~400-800** ~590-990** ~600-1000** ~885-1285** * Term formula generally contains 400-410 IU/L, transitional or post-discharge preterm formulas contain 520-590 IU/L 433 of vit. D. **A range is presented to represent infants on and off supplements after discharge. Total milk intake 434 increases over time, with the volumes listed representing a typical progression in the first several months of age.
436
We have selected the current supplementation dosing because we do not feel that a dosing strategy with a 437 total daily intake of <200 IU is safe or ethical due to the risk of rickets. Conversely, although studies in a 438 northern Finland cohort showed an association between supplement doses >2000 IU/day and allergy and 439 atopy later in life, our preliminary data in black infants and the Milner (2004) cohort study showing increased 440 asthma and allergy among supplemented black infants suggest an association at much lower doses in this 441 population; both of these studies were based on over-the-counter vitamin use, which corresponded to 442 recommended doses of 200-400 IU/day. 2 94-96 With concerns about adverse effects at supplementation doses 443 of 400 IU/day, and the current IOM recommendations to limit total (diet + supplement) intake to <1000 IU/day, 444
we also do not feel that it would be ethical to expose this population to higher doses before the safety of the 445 400 IU supplement is established with regards to wheezing and allergy. The current dosing strategy 446 nevertheless allows for separation of total dietary intake of vit. D of 400 IU/day between the treatment groups 447 (table 4) .
448
The vitamin supplements that will be used (multivitamins and D-only preparations) with a concentration of 400 449 IU/ml of D3 are commercially available over-the-counter and are generally considered to be safe. Inclusion and 450 exclusion criteria listed in the protocol are intended to exclude infants for whom the dosing strategies in the 451 protocol may not be appropriate (for instance, those with severe osteopenia). Infants on study supplement with 452 levels <15 ng/ml or >85 ng/ml at follow-up will stop their masked supplement and their levels will be reported to 453 their primary care provider for management; they will continue with their follow-up visits.
454
In Cleveland, study supplements will be dispensed by the MetroHealth investigational pharmacy for the 455 MetroHealth inpatients, and by the University Hospitals investigational pharmacy for the University Hospitals 456 inpatients and all outpatients, in order to standardize the packaging and delivery of masked supplement. At 457 other sites, the local research pharmacists will dispense study drug in accordance with study, site, and federal 458 procedures. Masked supplement will be prepared under standardized sterile conditions and in compliance with 459 pediatric pharmacy best practices and regulations. The placebo will be Ora-Sweet SF commercially available 460 flavored pediatric compounding solution that is sugar-free and alcohol-free. Since infants in both arms will be 461 switched from a multivitamin to either the masked vit. D or placebo, no family will receive both the D-only 462 product and the placebo for direct comparison. Study meds will be delivered to the home monthly by the 463 research nurse or FedEx. The first time an infant is taking >200 IU/day from diet and is switched to masked 464 D/placebo, the study supplement will be given to the family by the research nurse in person to reinforce 465 medication dosing and teaching. Any remaining supplements from the previous months will be weighed by the 466 research nurse at each visit to assess compliance.
468
Performance Sites: Infants will be recruited from two hospitals that are affiliated with CWRU that have level III Because the incidence of binary composite outcomes, such as recurrent wheezing, is not likely to be small, 490 relative risks (RR) and odds ratios (OR) will not be similar, and so binary outcomes will be modeled using a 491
Poisson regression model to estimate RR and a logistic regression model to estimate OR. Secondary analyses 492 will include an interaction between GA and arm to investigate if the treatment effect on each outcome differs by 493 GA. Continuous or binary outcomes that are measured at repeated times (such as allergy or eczema) will be 494 modeled using generalized linear mixed models that model the correlated data among an infant over time 495 using random intercepts and slopes. These models will include treatment arm and time since randomization to 496 allow us to estimate the average treatment effects on responses over time. Additional models will include an 497 interaction between treatment arm and GA, as well as treatment arm and time, to estimate the average 498 treatment effect on the response at 3, 6, 9, and 12 mo. adjusted age. Unless otherwise specified, a 0.05 two-499 sided significance level will be used for all analyses. All analyses will be performed using SAS 9.2. 500
Covariate adjustment: Although imbalance between the arms will only occur by chance due to randomization, 501 secondary analyses will include models that adjust for time since randomization, enrollment site, breast milk 502 exposure at enrollment, Synagis, and GA. While covariate adjustment in a clinical trial setting may ensure 503 achievement of the correct significance level as well as increase statistical power, if a covariate is not strongly 504 related to an outcome but is imbalanced between arms, adjustment for an imbalanced covariate is not required 505 and in fact, will decrease the precision and dilute the impact of the treatment when the outcome is binary (such 506 as recurrent wheezing). 140 Consequently, baseline variables that have a statistically significant unadjusted 507 association with the outcome of interest (based on a significance level of 0.10) will also be included as 508 covariates in secondary analyses, regardless of whether or not the variable is "balanced" among treatment 509 arms. 510
Adherence: Adherence will be measured at 3, 6, 9, and 12 mo. using the amount of remaining supplement 511 during the previous 3 months. Because this study also blinds families, treating physicians, and study staff to 512 the assigned strategy, we expect adherence to be similar between the two arms. Using a generalized mixed 513 model, we will test this assumption by estimating the average difference in adherence between the two arms 514 over time. We do not plan to use adherence as a covariate in the analyses or to perform subgroup analyses in 515 adherent patients only as it is well known that such analyses will produce a biased treatment effect.
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Model fit: The fit of each model will also be tested using residual analysis and appropriate action will be taken if 517 there is evidence of lack of fit (e.g. transformations or categorization of covariates or outcomes, sensitivity 518 analyses to gauge effect of outliers on outcomes of interest, etc.).
519
Accounting for correlated data within twin pairs: We expect ~10% of all mothers will have twins where both 520 twins will be randomized to the same arm. Standard methods for accounting for correlated data among twins 521 (GEE, mixed models, etc.) may not converge due to the small number of twin pairs. Consequently, multiple 522 outputation will be used to ensure that correlated data among twins is appropriately modeled.
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Interim analysis: One interim analysis will be performed after one-half of the sample completes the 6-month 524 follow-up. Recurrent wheezing will be the primary focus of planned interim analyses of efficacy and safety, 525 although secondary outcomes will also be presented. Details of the interim analysis are in the Data Safety 526
Monitoring Plan (DSMP).
527
Missing data: We estimate a 15% rate of drop-out throughout the study. For composite outcomes (such as 528 recurrent wheezing), the models discussed assume that data are completely missing at random while for 529 outcomes measured at multiple time points, the models discussed assume that data are missing at random. 530
However, it is likely that data will be missing not at random and so sensitivity analyses will be conducted to 531 ascertain the effect of missing data on the estimated treatment effects. In particular, a model based approach 532 that jointly models the response to treatment and the drop-out process will be used.
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533 Aim 1: We will model the RR (or OR) of recurrent wheezing between the two arms using a Poisson (or logistic) 534 regression model. Assuming that the rate of recurrent wheezing with Strategy II is 30%, and a two-sided 535 significance level of 0.05, a sample size of 115 infants per group will detect a RR of 1.6 with 80% power. 536
Allowing for ~15% loss to follow-up and ~10% of all mothers having twins where both twins are randomized to 537 the same arm, it is expected that a sample size of 300 infants (230/0.85*1.1) will be obtained. Consequently, 538
we expect that this estimate of power is conservative. 539
Aim 2: The main marker for allergic sensitization for this aim will be the Phadiatop Infant® assay. We will 540 estimate the OR of sensitization between Arm I and II using a logistic regression model and the RR using a 541
Poisson regression model. In one study, 21% of two-year-olds had a positive Phadiatop Infant test.
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Aeroallergen sensitization rates as high as 18-31% have been reported in high risk infant cohorts. Assuming 543 that the rate of sensitization with Arm II is 20% and a two-sided significance level of 0.05, a sample size of 115 544 infants per group will detect a OR of 2.31 with 80% power. Clinical symptoms of allergy or eczema will be 545 measured by questionnaires. In this case, we will model the average RR of allergy or eczema between the two 546 arms over time using a generalized linear mixed model assuming a Poisson distribution and the average OR of 547 allergy or eczema between the two arms over time using a generalized linear mixed model assuming a 548 binomial distribution. Approximately 15%-18% of infants suffer from eczema. [144] [145] [146] Estimates of the prevalence 549 of objectively measured food allergies in infants and toddlers range widely from approximately 2-5%. 125 147 If we 550 conservatively assume an average rate of eczema or allergy in Arm II of 15%, a correlation of 0.5 among 551 repeated measures, and a two-sided significance level of 0.05, a sample size of 115 infants per group will 552 detect an average OR over time of 2.06 with 80% power.
553
Aim 3: We will use a logistic (or Poisson) regression model to estimate the OR (or RR) of recurrent wheezing 554 per 1 unit increase in 25(OH)D3 level. Because 25(OH)D3 levels are measured at enrollment, 3 months, and 6 555 months, levels will be entered into the logistic or Poisson regression models in 1 of 2 ways: 1) each measure of 556 25(OH)D3 will be included in the model (separately or simultaneously); or 2) the level of vit. D received over 6 557 months will be summarized using the average of the three 25(OH)D3 measures. If all 3 measures of 25(OH)D3 558 are included in the model simultaneously, spurious results may occur if they are collinear. Although steps will 559 be taken to reduce multi-colinearity (e.g., centering), if the correlation among the three 25(OH)D3 measures is 560 higher than 0.70, each level will only be included in the models separately. To address our hypothesis of a U-561 shaped association between 25(OH)D3 and recurrent wheezing, the association between 25(OH)D3 and 562 recurrent wheezing will be modeled using a restricted cubic spline with knots defined using the quintiles or 563 quantiles of 25(OH)D3 levels. Using Wald-type contrasts, if our data suggests a simpler association between 564 25(OH)D3 and recurrent wheezing (e.g., a quadratic or piecewise linear association), this association will be 565 simplified accordingly. Because subjects with lower levels of 25(OH)D3 may not be comparable to subjects 566 with higher levels (despite randomization), adjustment for baseline covariates will be required in the primary 567 analysis for this aim using the criteria for covariate adjustment discussed previously. 568 569
C4. Limitations and Rationale for Proposed Approach: 570
Although some experts have recommended higher levels of supplementation than proposed for strategy II, we 571 feel that safety must be established first, given the preliminary data supported by the literature suggesting 572 harm in this population, given the recent FDA warning about the risk of adverse events in infants 573 unintentionally exceeding 400 IU/day of supplementation, and given the IOM recommendation to limit total 574 intake to <1000 IU/day. 2 105 138 Others might question whether study subjects should be exposed to the enteral 575 vit. D amounts in strategy I, due to the suggestion of increased wheezing illnesses with vit. D supplementation. 576
However, the population of black preterm infants in Cleveland is at high risk for vit. D deficiency, and we do not 577 believe clinical practice should be changed to restrict vit. D supplementation based on observational data 578 alone. In short, while a rationale exists for both higher and lower dosing, given the suggestion of competing 579 benefits and morbidity with supplementation, and the paucity of studies measuring clinically relevant outcomes 580 in this population, we believe equipoise exists for this study.
581
This is an effectiveness study comparing two dosing strategies that could practically be used by pediatricians.
582
We have not targeted specific plasma levels of 25(OH)D3, because (1) it would be impractical to routinely 583 finely titrate supplementation dose to a target level on all healthy preterm infants, and (2) the optimal levels in 584 this population are not known. Aim 3 will assess the relationship between levels and recurrent wheezing.
585
Recruitment and retention are challenges for all clinical studies. The research team has a track record for 586 success with similar populations. Examples of proven strategies include using experienced research nurses 587 with a prior history of serving the local community through clinical care, and frequent contact with families (e.g., 588
sending birthday cards hand-written by the PI). If we are not on-target for recruitment, we will consider 589 additional strategies, including expanding enrollment to other CWRU-affiliated NICUs. 590 591 C5. Summary: We propose a comparative effectiveness trial of two clinically relevant vit. D supplementation 592 strategies, focusing on outcomes that are meaningful to patients and providers. The results of this study have 593 the potential to improve care for the >100,000 black infants born at 28-36 wks GA in the U.S. yearly. 
